88 related articles for article (PubMed ID: 27894413)
1. Targeting of BCR-ABL: Lessons learned from BCR-ABL inhibition.
Lin X; Qureshi MZ; Attar R; Khalid S; Tahir F; Yaqub A; Aslam A; Yaylim I; De Carlos Back LK; Farooqi AA; Ismail M
Cell Mol Biol (Noisy-le-grand); 2016 Oct; 62(12):129-137. PubMed ID: 27894413
[TBL] [Abstract][Full Text] [Related]
2. While at Rome miRNA and TRAIL do whatever BCR-ABL commands to do.
Farooqi AA; Nawaz A; Javed Z; Bhatti S; Ismail M
Arch Immunol Ther Exp (Warsz); 2013 Feb; 61(1):59-74. PubMed ID: 23229677
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of crosstalk between Bcr-Abl and PKC signaling by PEITC, augments imatinib sensitivity in chronic myelogenous leukemia cells.
Roy M; Sarkar R; Mukherjee A; Mukherjee S
Chem Biol Interact; 2015 Dec; 242():195-201. PubMed ID: 26456889
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.
Yang K; Fu LW
Crit Rev Oncol Hematol; 2015 Mar; 93(3):277-92. PubMed ID: 25500000
[TBL] [Abstract][Full Text] [Related]
5. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
Liao HF; Su YC; Zheng ZY; Jhih Cai C; Hou MH; Chao KS; Chen YJ
Biomed Pharmacother; 2012 Jul; 66(5):378-83. PubMed ID: 22397755
[TBL] [Abstract][Full Text] [Related]
6. Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment.
Hershkovitz-Rokah O; Modai S; Pasmanik-Chor M; Toren A; Shomron N; Raanani P; Shpilberg O; Granot G
Cancer Lett; 2015 May; 360(2):245-56. PubMed ID: 25697481
[TBL] [Abstract][Full Text] [Related]
7. Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer.
Brechbiel J; Miller-Moslin K; Adjei AA
Cancer Treat Rev; 2014 Jul; 40(6):750-9. PubMed ID: 24613036
[TBL] [Abstract][Full Text] [Related]
8. Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation.
Melo JV; Deininger MW
Hematol Oncol Clin North Am; 2004 Jun; 18(3):545-68, vii-viii. PubMed ID: 15271392
[TBL] [Abstract][Full Text] [Related]
9. [New approach in the diagnosis and monitoring of treatment in chronic myelogenous leukemia].
Matolcsy A
Orv Hetil; 2004 Dec; 145(52):2603-9. PubMed ID: 15724695
[TBL] [Abstract][Full Text] [Related]
10. BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib.
Gadzicki D; von Neuhoff N; Steinemann D; Just M; Büsche G; Kreipe H; Wilkens L; Schlegelberger B
Cancer Genet Cytogenet; 2005 Jun; 159(2):164-7. PubMed ID: 15899391
[TBL] [Abstract][Full Text] [Related]
11. Recognition of the ALL-specific BCR-ABL junction in P190bcr-abl by monoclonal antibody ER-FP1.
van Denderen J; ten Hacken P; Berendes P; Zegers N; Boersma W; Grosveld G; van Ewijk W
Leukemia; 1994 Sep; 8(9):1503-9. PubMed ID: 8090030
[TBL] [Abstract][Full Text] [Related]
12. Complex chromosome rearrangements may locate the bcr/abl fusion gene sites other than 22q11.
Sessarego M; Fugazza G; Bruzzone R; Ballestrero A; Miglino M; Bacigalupo A
Haematologica; 2000 Jan; 85(1):35-9. PubMed ID: 10629589
[TBL] [Abstract][Full Text] [Related]
13. Abl: the prototype of oncogenic fusion proteins.
Saglio G; Cilloni D
Cell Mol Life Sci; 2004 Dec; 61(23):2897-911. PubMed ID: 15583852
[TBL] [Abstract][Full Text] [Related]
14. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.
von Bubnoff N; Peschel C; Duyster J
Leukemia; 2003 May; 17(5):829-38. PubMed ID: 12750693
[TBL] [Abstract][Full Text] [Related]
15. Chronic myelocytic leukemia--Part I: History, clinical presentation, and molecular biology.
Randolph TR
Clin Lab Sci; 2005; 18(1):38-48. PubMed ID: 15747785
[TBL] [Abstract][Full Text] [Related]
16. Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.
Deininger MW; Vieira SA; Parada Y; Banerji L; Lam EW; Peters G; Mahon FX; Köhler T; Goldman JM; Melo JV
Cancer Res; 2001 Nov; 61(21):8005-13. PubMed ID: 11691826
[TBL] [Abstract][Full Text] [Related]
17. Establishment and molecular characterization of a novel leukemic cell line with Philadelphia chromosome expressing p230 BCR/ABL fusion protein.
Wada H; Mizutani S; Nishimura J; Usuki Y; Kohsaki M; Komai M; Kaneko H; Sakamoto S; Delia D; Kanamaru A
Cancer Res; 1995 Jul; 55(14):3192-6. PubMed ID: 7606740
[TBL] [Abstract][Full Text] [Related]
18. A novel variant of the bcr-abl fusion product in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Soekarman D; van Denderen J; Hoefsloot L; Moret M; Meeuwsen T; van Baal J; Hagemeijer A; Grosveld G
Leukemia; 1990 Jun; 4(6):397-403. PubMed ID: 2193202
[TBL] [Abstract][Full Text] [Related]
19. Modeling Philadelphia chromosome positive leukemias.
Wong S; Witte ON
Oncogene; 2001 Sep; 20(40):5644-59. PubMed ID: 11607816
[TBL] [Abstract][Full Text] [Related]
20. Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis.
Puccetti E; Beissert T; Güller S; Li JE; Hoelzer D; Ottmann OG; Ruthardt M
Oncogene; 2003 Oct; 22(44):6900-8. PubMed ID: 14534537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
